Alumis Inc. (NASDAQ:ALMS – Get Free Report)’s share price hit a new 52-week low on Monday after Oppenheimer lowered their price target on the stock to $28.00. Oppenheimer currently has an outperform rating on the stock. Alumis traded as low as $5.22 and last traded at $5.1960, with a volume of 319,044 shares changing hands. The stock had previously closed at $5.60.
A number of other brokerages have also commented on ALMS. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a report on Wednesday, September 16th. Wells Fargo & Company cut their price objective on shares of Alumis from $25.00 to $18.00 and set an “overweight” rating on the stock in a research note on Friday. Guggenheim downgraded shares of Alumis from a “buy” rating to a “neutral” rating in a report on Thursday, September 3rd. Weiss Ratings upgraded shares of Alumis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Finally, Wall Street Zen lowered shares of Alumis from a “hold” rating to a “sell” rating in a research report on Saturday, September 5th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.27.
View Our Latest Research Report on Alumis
Insiders Place Their Bets
In other Alumis news, Director Srinivas Akkaraju sold 96,131 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $10.55, for a total value of $1,014,182.05. Following the completion of the sale, the director directly owned 2,025,493 shares in the company, valued at $21,368,951.15. This represents a 4.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 99,754 shares of company stock valued at $1,037,804 in the last three months. Corporate insiders own 33.70% of the company’s stock.
Institutional Trading of Alumis
A number of hedge funds and other institutional investors have recently modified their holdings of ALMS. BlackRock Inc. bought a new position in Alumis during the second quarter valued at about $231,259,000. venBio Partners LLC acquired a new position in Alumis during the second quarter worth about $127,429,401. Jupiter Topco LLC bought a new stake in Alumis in the second quarter worth about $66,238,000. Octagon Capital Advisors LP raised its position in Alumis by 11.9% in the first quarter. Octagon Capital Advisors LP now owns 2,830,700 shares of the company’s stock worth $62,360,000 after acquiring an additional 300,000 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new stake in Alumis in the first quarter worth about $46,790,000.
Alumis Stock Performance
The company has a market capitalization of $662.06 million, a price-to-earnings ratio of -1.47 and a beta of -0.28. The stock’s fifty day simple moving average is $7.24 and its two-hundred day simple moving average is $20.46.
Alumis (NASDAQ:ALMS – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.03. The company had revenue of $1.91 million during the quarter, compared to analyst estimates of $1.90 million. Alumis had a negative net margin of 5,844.54% and a negative return on equity of 89.77%. On average, equities analysts anticipate that Alumis Inc. will post -2.95 EPS for the current fiscal year.
About Alumis
Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments. Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use.
See Also
- Five stocks we like better than Alumis
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- 3 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.
